title: Longitudinal association between medication adherence and lung health in people with cystic fibrosis.
abstract: BACKGROUND
  This study examined the relationship of medication adherence to frequency of pulmonary exacerbation and rate of decline in FEV(1)% predicted (FEV(1)).
  
  
  METHODS
  95 CF patients aged 6 years or older and prescribed a pulmonary medication, were enrolled in a longitudinal retrospective review of medication adherence and health outcomes (the occurrence and frequency of intravenous (IV) antibiotic treatments and FEV(1)) over 12-months. Pharmacy refill records were used to calculate a medication possession ratio (MPR).
  
  
  RESULTS
  Composite MPR predicted the occurrence of at least one pulmonary exacerbation requiring a course of IV antibiotics (IRR=2.34, p=0.05), but not the frequency of exacerbations, after controlling for gender, baseline FEV(1,) and regimen complexity. Composite MPR predicted baseline FEV(1) (estimate=29.81, p=.007), but not decline in FEV(1).
  
  
  CONCLUSIONS
  These results demonstrate a significant relation between medication adherence and IV antibiotics in CF patients, highlighting the importance of addressing adherence during clinic visits to improve health outcomes.
authors: Division of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21224, USA. meakin1@jhmi.edu
authors: Michelle N
authors: MN
authors: Eakin
authors: Andrew
authors: A
authors: Bilderback
authors: Michael P
authors: MP
authors: Boyle
authors: Peter J
authors: PJ
authors: Mogayzel
authors: Kristin A
authors: KA
authors: Riekert
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D017963:Azithromycin / Q000008:administration & dosage; D002648:Child; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000503:physiopathology; D003850:Deoxyribonuclease I / Q000008:administration & dosage*; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008137:Longitudinal Studies; D008297:Male; D017063:Outcome Assessment, Health Care; D010604:Pharmacy / Q000706:statistics & numerical data; D012189:Retrospective Studies; D014031:Tobramycin / Q000008:administration & dosage*; D055815:Young Adult; D016903:Drug Monitoring
chemical_list: D000900:Anti-Bacterial Agents; D017963:Azithromycin; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I; D014031:Tobramycin